From Clinical to Commercial: Accelerating ADC Late-Stage Development With Technology Innovation and an Integrated Platform
ByWuXi XDC
Webcasts
Webinar Date/Time: Thu, Nov 19, 2026 11:00 AM EST
WuXi XDC
Advertisement
Articles by WuXi XDC
Accelerate Next-Generation Bioconjugate Development through an Innovative Technology Platform
ByWuXi XDC
Sponsored Content
The path to ADC success demands precision – from DAR optimization and linker stability to rigorous safety profiling! Discover how novel conjugation and payload-linker platform empowers the rational design of next-generation ADCs with enhanced therapeutic potential —improving efficacy, stability and safety.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Genmab’s Petosemtamab Plus Pembrolizumab Cuts Risk of Death by 50% in Phase 3 Head and Neck Cancer Trial
2
3SBio and Pfizer’s PD-1×VEGF Bispecific Shows Durable PFS Gains in First-Line NSCLC
3
The BioPharm Brief: A Survival Win, a Myeloma Filing, and Gene Therapy for Swallowing
4
Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup
5